PD-1抑制剂致免疫相关性心肌炎的病例分析
Case Analysis of Immune-Related Myocarditis Induced by PD-1 Inhibitors
DOI: 10.12677/ACM.2022.123280, PDF,   
作者: 史婉婷, 齐甜甜：青岛大学，山东 青岛；陈 剑*：青岛大学附属烟台毓璜顶医院肿瘤科，山东 烟台
关键词: PD-1抑制剂；免疫相关性心肌炎；病例分析；不良反应；PD-1 Inhibitors； Immune-Related Myocarditis； Case Analysis； Adverse Drug Reactions
摘要: 目的：总结PD-1单抗致免疫相关性心肌炎发生的规律、特点、治疗和预后。方法：回顾性分析2020年3月~2022年1月在青岛大学附属烟台毓璜顶医院进行PD-1单抗治疗的6例患者，总结其临床资料。结果：6例患者中，男性5例、女性1例，平均年龄为68.33岁；临床诊断肺癌4例、胃癌、结肠癌各1例；半数患者的免疫性心肌炎出现在使用PD-1抑制剂第一周期后，平均发生时间为末次用药后的20.83天。全部患者都使用了糖皮质激素处理且心功能都得到了恢复后均未再重启免疫治疗。结论：当患者使用PD-1抑制剂治疗时，需做好心脏功能相关基线检查和常规监测，如怀疑发生免疫相关性心肌炎，尽早完善心功能相关检查并使用大剂量糖皮质激素治疗，必要时可加用其他免疫抑制剂和其他对症治疗措施。
Abstract: Objective: To investigate the characteristics, treatment and prognosis of immune-related myocarditis induced by PD-1 inhibitors. Methods: We retrospectively analyzed the clinical data of 6 advanced tumor patients who received PD-1 inhibitors therapy in Qingdao Affiliated Yantai Yuhuangding Hospital from March 2020 to January 2022. Results: 6 patients were involved, including 5 males and 1 female, with an average age of 68.33 years. There were 4 cases of lung cancer, 1 case of gastric cancer, 1 case of colon cancer. Immunological myocarditis of 50% patients occurred after the first cycle of PD-1 inhibitors administration, and the average occurrence time was 20.83 days after the last administration. All patients were treated with glucocorticoids when they developed immune-associated myocarditis. Both the symptoms and cardiac function had recovered and none of these patients restarted with immunotherapy. Conclusions: Baseline examination and monitoring of cardiac function should be done when patients are treated with PD-1 inhibitors. Once immune-related myocarditis is suspected, cardiac function-related tests should be performed timely. Immediate initiation of high-dose glucocorticoid therapy and other immunosuppressant should be considered.
文章引用：史婉婷, 齐甜甜, 陈剑. PD-1抑制剂致免疫相关性心肌炎的病例分析[J]. 临床医学进展, 2022, 12(3): 1946-1953. https://doi.org/10.12677/ACM.2022.123280

参考文献

[1] Simsek, M., Tekin, S.B. and Bilici, M.J. (2018) Immunological Agents Used In Cancer Treatment. The Eurasian Journal of Medicine, 51, 90-94.
[Google Scholar] [CrossRef] [PubMed]
[2] Thompson, J.A., Schneider, B.J., Brahmer, J., Andrews, S. and Engh, A.J. (2020) NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. Journal of the National Comprehensive Cancer Network, 18, 230-241.
[Google Scholar] [CrossRef] [PubMed]
[3] Tajiri, K. and Ieda, M. (2019) Cardiac Complications in Immune Checkpoint Inhibition Therapy. Frontiers in Cardiovascular Medicine, 6, Article No. 3.
[Google Scholar] [CrossRef] [PubMed]
[4] 皋文君, 刘砚燕, 袁长蓉. 国际肿瘤化疗药物不良反应评价系统——通用不良反应术语标准4.0版[J]. 肿瘤, 2012, 32(2): 142-144.
[5] 中国抗癌协会整合肿瘤心脏病学分会, 中华医学会心血管病学分会肿瘤心脏病学学组, 中国医师协会心血管内科医师分会肿瘤心脏病学专业委员会, 中国临床肿瘤学会肿瘤心脏病学专家委员会. 免疫检查点抑制剂相关心肌炎监测与管理中国专家共识(2020版) [J]. 中国肿瘤临床, 2020, 47(20): 1027-1038. [Google Scholar] [CrossRef] 
[6] Moslehi, J.J., Salem, J.E., Sosman, J.A., Lebrun-Vignes, B. and Johnson, D. (2018) Increased Reporting of Fatal Immune Checkpoint Inhibitor-Associated Myocarditis. The Lancet, 391, 933.
[Google Scholar] [CrossRef] 
[7] Wang, F., Sun, X., Qin, S., Hua, H. and Yang, M. (2020) A Retrospective Study of Immune Checkpoint Inhibitor-Associated Myocarditis in a Single Center in China. Chinese Clinical Oncology, 9, Article No. 16.
[Google Scholar] [CrossRef] [PubMed]
[8] Wang, F., Qin, S.K., Lou, F., Chen, F.X., Shi, M.Q., Liang, X.H., Jiang, H., Jiang, Y., Chen, Y., Du, Y.Y., Xue, J., Zhu, H. and Ren, W. (2020) Retrospective Analysis of Immune Checkpoint Inhibitor-Associated Myocarditis from 12 Cancer Centers in China. Journal of Clinical Oncology, 3, e15130.
[Google Scholar] [CrossRef] 
[9] Advani, P.P., Ballman, K.V., Dockter, T.J., Colon-Otero, G. and Perez, E.A. (2016) Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial. Journal of Clinical Oncology, 34, 581-587.
[Google Scholar] [CrossRef] 
[10] 黄光明, 贺盛发, 黄振光, 张宏亮. 15例帕博利珠单抗致免疫相关性心肌炎的病例分析[J]. 中国药房, 2021, 32(6): 729-735.
[11] 崔亚萌, 齐新, 魏丽萍, 刘玥. 顺铂心脏毒性的研究进展[J]. 现代药物与临床, 2017, 32(2): 351-355.
[12] 董爽, 胡胜, 欧武陵, 蔡茜. 免疫检查点抑制剂的心脏毒性及其机制[J]. 肿瘤防治研究, 2018, 45(11): 858-863.
[13] 吴军. 抗肿瘤血管生成药物不良反应的发生机制及处理[J]. 医学综述, 2016, 22(16): 3154-3157.
[14] Lyon, A.R., Yousaf, N., Battisti, N.M.L., Moslehi, J. and Larkin, J. (2018) Immune Checkpoint Inhibitors and Cardiovascular Toxicity. The Lancet Oncology, 19, e447-e458.
[Google Scholar] [CrossRef] 
[15] Jain, V., Bahia, J., Mohebtash, M. and Barac, A. (2017) Cardiovascular Complications Associated With Novel Cancer Immunotherapies. Current Treatment Options in Cardiovascular Medicine, 19, Article No. 36.
[Google Scholar] [CrossRef] [PubMed]
[16] Bonaca, M.P., Olenchock, B.A., Salem, J.E., Wiviott, S.D., Ederhy, S., Cohen, A., Stewart, G.C., Choueiri, T.K., Di Carli, M., Allenbach, Y., Kumbhani, D.J., Heinzerling, L., Amiri-Kordestani, L., Lyon, A.R., Thavendiranathan, P., Padera, R., Lichtman, A., Liu, P.P., Johnson, D.B. and Moslehi, J. (2019) Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. Circulation, 140, 80-91.
[Google Scholar] [CrossRef] 
[17] Mahmood, S.S., Fradley, M.G., Cohen, J.V., Nohria, A., Reynolds, K.L., Heinzerling, L.M., Sullivan, R.J., Damrongwatanasuk, R., Chen, C.L., Gupta, D., Kirchberger, M.C., Awadalla, M., Hassan, M.Z.O., Moslehi, J.J., Shah, S.P., Ganatra, S., Thavendiranathan, P., Lawrence, D.P., Groarke, J.D. and Neilan, T.G. (2018) Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. Journal of the American College of Cardiology, 71, 1755-1764.
[Google Scholar] [CrossRef] [PubMed]
[18] Mir, H., Alhussein, M., Alrashidi, S., Alzayer, H., Alshatti, A., Valettas, N., Mukherjee, S.D., Nair, V. and Leong, D.P. (2018) Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area. The Canadian Journal of Cardiology, 34, 1059-1068.
[Google Scholar] [CrossRef] [PubMed]
[19] Nieminen, M.S., Heikkilä, J. and Karjalainen, J. (1984) Echocardiography in Acute Infectious Myocarditis: Relation to Clinical and Electrocardiographic Findings. The American Journal of Cardiology, 53, 1331-1337.
[Google Scholar] [CrossRef] [PubMed]
[20] Palaskas, N., Lopez-Mattei, J., Durand, J.B., Iliescu, C. and Deswal, A. (2020) Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. Journal of the American Heart Association, 9, e013757.
[Google Scholar] [CrossRef] 
[21] Atallah-Yunes, S.A., Kadado, A.J., Kaufman, G.P. and Hernandez-Montfort, J. (2019) Immune Checkpoint Inhibitor Therapy and Myocarditis: A Systematic Review of Reported Cases. Journal of Cancer Research and Clinical Oncology, 145, 1527-1557.
[Google Scholar] [CrossRef] [PubMed]
[22] Brahmer, J.R., Lacchetti, C., Schneider, B.J., Atkins, M.B., Brassil, K.J., Caterino, J.M., Chau, I., Ernstoff, M.S., Gardner, J.M., Ginex, P., Hallmeyer, S., Holter Chakrabarty, J., Leighl, N.B., Mammen, J.S., McDermott, D.F., Naing, A., Nastoupil, L.J., Phillips, T., Porter, L.D., Puzanov, I., Reichner, C.A., Santomasso, B.D., Seigel, C., Spira, A., Suarez-Almazor, M.E., Wang, Y., Weber, J.S., Wolchok, J.D. and Thompson, J.A. (2018) Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 36, 1714-1768.
[Google Scholar] [CrossRef] 
[23] Norwood, T.G., Westbrook, B.C., Johnson, D.B., Litovsky, S.H., Terry, N.L., McKee, S.B., Gertler, A.S., Moslehi, J.J. and Conry, R.M. (2017) Smoldering Myocarditis Following Immune Checkpoint Blockade. Journal for Immunotherapy of Cancer, 5, 91.
[Google Scholar] [CrossRef] [PubMed]
[24] Arangalage, D., Delyon, J., Lermuzeaux, M., Ekpe, K., Ederhy, S., Pages, C. and Lebbé, C. (2017) Survival after Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors. Annals of Internal Medicine, 167, 683-684.
[Google Scholar] [CrossRef] 
[25] Frigeri, M., Meyer, P., Banfi, C., Giraud, R., Hachulla, A.L., Spoerl, D., Friedlaender, A., Pugliesi-Rinaldi, A. and Dietrich, P.Y. (2018) Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists. The Canadian Journal of Cardiology, 34, 92.e1-92.e3.
[Google Scholar] [CrossRef] [PubMed]
[26] Tay, R.Y., Blackley, E., McLean, C., Moore, M., Bergin, P., Gill, S. and Haydon, A. (2017) Successful Use of Equine Anti-Thymocyte Globulin (ATGAM) for Fulminant Myocarditis Secondary to Nivolumab Therapy. British Journal of Cancer, 117, 921-924.
[Google Scholar] [CrossRef] [PubMed]

为你推荐